PMC9539026_01
Morphology, cytogenetic and Molecular analysis of a bone marrow sample of the APL patient with BCOR-RARA. (A) May-Giemsa staining. Original magnification x 400. (B) Karyotype analysis. 42, X, -Y, -15, -16, -18 was detected in the patient. (C) BCOR-RARA fusion sequence at the junction site. An in-frame BCOR-RARA transcript is shown with corresponding exon numbers. The junction is indicated by a red arrowhead. (D) Schematic representation of BCOR, RARA, and the BCOR-RARA fusion protein. BCOR-RARA protein retains both BCOR and ANK of BCOR and ZnF_C4 and NR_LBD of RARA. ANK, ankyrin repeats; PUFD, PCGF Ub-like fold discriminator of BCOR; NR_LBD_RAR, the ligand binding domain (LBD) of retinoic acid receptor (RAR); ZnF_C4, c4 zinc finger in nuclear hormone receptors; HOLI, Ligand binding domain of hormone receptors.
fonc-12-1013046-g001.jpg
PMC9539026_01_fonc-12-1013046-g001.jpg
f1
Figure 1A ). Flow cytometry revealed that the abnormal cells expressed CD13, CD33, CD117, CD38, CD56, but lacked the expression of CD34, CD15, CD14 and HLA-DR. Tong University School of Medicine. The karyotype analysis indicated 42, X, -Y, -15, -16, -18[cp12] ( Figure 1B ). Figures 1C, D ). Furthermore, we performed targeted next-generation sequencing (NGS) covering 100 genes reportedly mutated in myeloid leukemia.
Timeline with the main events of the clinical episode for the patient.
fonc-12-1013046-g002.jpg
PMC9539026_01_fonc-12-1013046-g002.jpg
f2
Until now, he has maintained a molecular CR status for more than 9 months after HSCT.  Figure 2  shows the detailed events of the clinical episode for the patient.